You have likely heard from numerous medical professionals that Myeloma is "treatable but not curable" right? WRONG! Banish that thought from your mind now as it is completely and utterly False! I know Multiple Myeloma can be cured because I have witnessed it firsthand and if you want to understand how it can be cured look no further than this book . In addition to revealing a number of sources where you can purchase the most effective calcium supplements that the authors close family member used to heal themselves from a level III diagnosis to "stringent complete response" or total remission of Myeloma.
This book presents the forefront in the science and clinical management of myeloma bone disease. Coverage begins with sections on clinical presentation, imaging, and biochemical markers and goes on to discuss radiation, surgical, and medical therapies.
This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.
The definitive guide to living a longer, fuller life with myeloma The Myeloma Survival Guide makes sense of the difficult questions myeloma patients face, dealing with every aspect of life after diagnosis, from creating a wellness team to navigating treatment options to building a financial safety net. Jim Tamkin, MD, who lived with myeloma for 11 years, and Dave Visel share the insights they've gained as a doctor, patient, and caregiver, including: Everything you need to know about drugs and treatments, including stem cell transplants How to deal with the pain and side effects of chemotherapy, radiation, and surgery Insurance and tax benefits to save money and get you the care you deserve Take-charge tools you can use today to feel better tomorrow The second edition has been thoroughly updated and includes a new chapter on pills and medical adherence. "An invaluable guide to patients with newly diagnosed multiple myeloma. Not only have they provided clear information on the disease and its treatment, but most importantly also convey critical guidance on how to deal with the very personal life-impacting effects of this disease for patients and family members alike." –Kenneth C. Anderson, MD, Kraft Family Professor of Medicine, Harvard Medical School, and Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute Jim Tamkin, MD, FACP, FACE, lived with myeloma for 11 years. He co-founded the TBA (Their Best Advice) Foundation with Dave Visel in 2009 to provide myeloma patients with the resources they need to cope with the disease. He worked as an internist and endocrinologist in Los Angeles until his death in March 2011. Dave Visel is co-founder of the TBA Foundation and author of Living with Cancer: A Practical Guide. He is a retired advertising copywriter and marketing executive, and is a caregiver to his wife, Karen, who has leukemia. They live in Los Angeles. www.TBAfoundation.org
Hypercalcemia is the most common life-threatening metabolic disorder associated with cancer. The pathophysiological, epidemiological and clinical aspects of hypercalcemia of malignancy are presented in this issue, with a focus on the recently discovered humoral factor responsible for the development of hypercalcemia. With a better understanding of the pathophysiology of this condition and the development of new potent drugs, capable of inhibiting bone resorption, especially bisphosphonates, the clinician will be more successful in correcting hypercalcemia in the great majority of patients.
This book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma. It is divided into three main sections that cover a wide range of topics, including: epidemiology and pathogenesis of the disease, genetic targets and pathways, resistance to novel therapies, angiogenesis and anti-angiogenesis, hematopoietic stem cell transplantation, role of radiology and radiotherapy in myeloma, infectious complications, and management of multiple myeloma in resource-poor countries.
Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy, including in particular the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life.
James Bond's survival of multiple myeloma since 1992 is an amazing story of tenacity, hard work and good fortune. In this book Jim shares his and his caregiver wife's, Kathleen, approaches and experiences and difficulties. This book provides two acronyms Jim developed that summarize their approaches to surviving a deadly, incurable blood cancer. Multiple myeloma's average survival is about 5 years. There is no cure, yet. Jim primarily is treated in Cleveland at University Hospital's Seidman Cancer Center and the Dana Farber Cancer Institute in Boston, with second opinions from Mayo Clinic and Mass. General doctors specializing in multiple myeloma. They continue to share their story, which they have done in over 30 US states, Washing DC at the National Academy of Science, and in Canada, Spain and Japan. They welcome opportunities to help other multiple myeloma patients and caregivers by sharing their experiences. They do not give medical or drug advice in their talks nor in this book. They live in greater Cleveland, Ohio and enjoy their 2 grown boys, their wives, and 3 grandchildren. Searching Jim's name and multiple myeloma provides much of their story and contact information.
This book provides the reader with a comprehensive understanding of both the basic principles and the clinical applications of nuclear oncology imaging techniques. The authors have assembled a distinguished group of leaders in the field who provide valuable insight on the subject. The book also includes major chapters on the cancer patient and the pathophysiology of abnormal tissue, the evaluation of co-existing disease, and the diagnosis and therapy of specific tumors using functional imaging studies. Each chapter is heavily illustrated to assist the reader in understanding the clinical role of nuclear oncology in cancer disease therapy and management.
This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.
